Clovis Oncology (CLVS) takeover chatter may be overdone - TheStreet
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Clovis Oncology (NASDAQ: CLVS) takeover chatter may be overdone - TheStreet
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Chardan Capital Markets Starts Clovis Oncology (CLVS) at 'Sell' With Price Target of $15
- tronc (TRNC) Trades Lower as Gannett (GCI) Deal in Doubt as Banks Withdraw Funding - Bloomberg
- Exxon Mobil (XOM) weekly option implied volatility increases to 37 into Q3 and outlook
Create E-mail Alert Related CategoriesRumors, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!